Mamaearth Parent Honasa Allots 5.79 Lakh Equity Shares Under ESOP Plans

Honasa Consumer Ltd, which owns new-age FMCG brands like Mamaearth and The Derma Co, has approved the allotment of 5,79,849 equity shares to its eligible employees under its employee stock option plan (ESOP). 

“We wish to inform you that the Nomination and Remuneration Committee of the Company vide circular resolution passed on September 02, 2024, has approved the allotment of 5,79,849 equity shares,” Honasa said in a regulatory filing. 

Of these, 5,46,601 shares were approved for allotment under Honasa Consumer Limited Employee Stock Option Plan 2018 and 33,248 under Honasa Consumer Limited Employee Stock Option Plan 2021. 

The allotted shares are worth INR 29.23 Cr as per Honasa’s closing price at the end of Monday’s trading session.  

Of 5,46,601 shares under ESOP 2018, 4,26,454 have been granted with an exercise price of INR 20.43 while the remaining 1,20,147 were issued at INR 252.41 exercise price.

After the allotment, Honasa’s issued, subscribed and paid-up equity share capital will increase to 32.48 Cr from 32.42 Cr. 

This ESOP expansion comes a month after Honasa allocated 3,97,169 shares to its eligible employees under its ESOP 2018 in August. 

Before that, in 2021, Honasa granted ESOPs worth INR 20 Cr for all their employees. 

Founded in 2016 by the husband-wife duo Varun and Ghazal Alagh, Honasa’s product portfolio comprises six beauty and personal care brands which include Mamaearth, The Derma Co., Aqualogica, Ayuga, BBlunt and Dr. Sheth’s.

It posted a 62.9% jump in its profit after tax (PAT) to INR 40.2 Cr in the June quarter (Q1) of the financial year 2024-25 (FY25) from INR 24.7 Cr in the same quarter of the previous year. This jump came on the back of an increase in the sales of its beauty products. 

Its operating revenue witnessed a strong growth of 19.3% on a year-on-year (YoY) basis and 17.3% sequentially to increase to INR 554 Cr in the reported quarter. In line with its growth, Honasa’s total expenses jumped 17.4% to INR 520.4 Cr in Q1 FY25 from INR 443.1 Cr in the corresponding quarter last year.

Note: We at Inc42 take our ethics very seriously. More information about it can be found here.